Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q9ULZ2 (
STAP1
)
11
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tec, Btk, Itk, Bmx, and Txk constitute the Tec family of protein tyrosine kinases (PTKs), a family with the distinct feature of containing a pleckstrin homology (PH) domain. Tec acts in signaling pathways triggered by the B cell antigen receptor (BCR), cytokine receptors, integrins, and receptor-type PTKs. Although upstream regulators of Tec family kinases are relatively well characterized, little is known of the downstream effectors of these enzymes. The yeast two-hybrid system has identified several proteins that interact with the kinase domain of Tec, one of which is now revealed to be a previously unknown docking protein termed
BRDG1
(
BCR downstream signaling 1
).
BRDG1
contains a proline-rich motif, a PH domain, and multiple tyrosine residues that are potential target sites for Src homology 2 domains. In 293 cells expressing recombinant
BRDG1
and various PTKs, Tec and Pyk2, but not Btk, Bmx, Lyn, Syk, or c-Abl, induced marked phosphorylation of
BRDG1
on tyrosine residues.
BRDG1
was also phosphorylated by Tec directly in vitro. Efficient phosphorylation of
BRDG1
by Tec required the PH and SH2 domains as well as the kinase domain of the latter. Furthermore,
BRDG1
was shown to participate in a positive feedback loop by increasing the activity of Tec.
BRDG1
transcripts are abundant in the human B cell line Ramos, and the endogenous protein underwent tyrosine phosphorylation in response to BCR stimulation.
BRDG1
thus appears to function as a docking protein acting downstream of Tec in BCR signaling.
...
PMID:Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase. 1051 61
This review addresses the contribution of some genes to the phenotype of familial hypercholesterolemia. At present, it is known that the pathogenesis of this disease involves not only a pathological variant of low-density lipoprotein receptor and its ligands (apolipoprotein B, proprotein convertase subtilisin/kexin type 9 or low-density lipoprotein receptor adaptor protein 1), but also lipids, including sphingolipids, fatty acids, and sterols. The genetic cause of familial hypercholesterolemia is unknown in 20%-40% of the cases. The genes
STAP1
(
signal transducing adaptor family member 1
),
CYP7A1
(cytochrome P450 family 7 subfamily A member 1),
LIPA
(lipase A, lysosomal acid type),
ABCG5
(ATP binding cassette subfamily G member 5),
ABCG8
(ATP binding cassette subfamily G member 8), and
PNPLA5
(patatin like phospholipase domain containing 5), which can cause aberrations of lipid metabolism, are being evaluated as new targets for the diagnosis and personalized management of familial hypercholesterolemia.
...
PMID:Genes Potentially Associated with Familial Hypercholesterolemia. 3179 97